Form 4 for WVE Wave Life Sciences, Inc.
Accepted 2026-02-11 00:00:00 ET · period of report 2026-02-05 · accession 0001193125-26-047323 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-11 | 2026-02-05 | WVE | Moran Kyle | CFO | A - Grant | $0.00 | +45.6K | 138.0K | +49% | $0 |
| D | 2026-02-11 | 2026-02-09 | WVE | Moran Kyle | CFO | S - Sale | $13.45 | -3,588 | 134.4K | -3% | -$48.3K |
| D | 2026-02-11 | 2026-02-05 | WVE | Moran Kyle | CFO | A - Grant | $0.00 | +273.8K | 273.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-02-05 | A | A | 45,625 | $0.00 | 137,973 | D | — | — | (F1) Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. (F2) Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan. |
| 2 | Common | Ordinary Shares | 2026-02-09 | S | D | 3,588 | $13.45 | 134,385 | D | — | — | |
| 3 | Derivative | Share Option (right to buy) | 2026-02-05 | A | A | 273,750 | $0.00 | 273,750 | D | $12.75 · — to 2036-02-05 | 273,750 Ordinary Shares | (F4) The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. |